UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 70

Sortiert nach

Reporting of sexually transmitted infections during the COVID-19 pandemic

Sexually transmitted infections, 2021-03, Vol.97 (2), p.101

2021

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Position on the Recent Judicial Challenge of U.S. Food and Drug Administration Approval of Mifepristone

Journal of medical toxicology, 2023-10, Vol.19 (4), p.414-415

2023

Link zum Volltext

Verfügbarkeit prüfen

Reporting of Infectious Diseases in the United States During the Coronavirus Disease 2019 (COVID-19) Pandemic

Clinical infectious diseases, 2022-03, Vol.74 (5), p.901-904

2022

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Role of the Medical Toxicologist in the Management of Patients with Substance Use Disorder

Journal of medical toxicology, 2023-10, Vol.19 (4), p.411-413

2023

Link zum Volltext

Verfügbarkeit prüfen

Case Series: Pneumorrhachis Secondary to Spontaneous Pneumomediastinum

The Journal of emergency medicine, 2016-02, Vol.50 (2), p.e43-e45

2016

Link zum Volltext

Verfügbarkeit prüfen

Bradycardia and Hypotension after Synthetic Cannabinoid Use: A Case Series

The American journal of emergency medicine, 2016-10, Vol.34 (10), p.2055.e1-2055.e2

2016

Link zum Volltext

Verfügbarkeit prüfen

Severe prolonged agitation due to intranasal naloxone overexposure

The American journal of emergency medicine, 2021-04, Vol.42, p.261.e1-261.e2

2021

Link zum Volltext

Verfügbarkeit prüfen

American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time

Clinical toxicology (Philadelphia, Pa.), 2023-11, Vol.61 (11), p.952-955

2023

Link zum Volltext

Verfügbarkeit prüfen

The Landscape of Prescription Drug Shortages During the COVID-19 Pandemic

Journal of medical toxicology, 2020-07, Vol.16 (3), p.311-313

2020

Link zum Volltext

Verfügbarkeit prüfen

Ensuring the Efficacy and Safety of Approved Medications

Journal of medical toxicology, 2024-04, Vol.20 (2), p.81-83

2024

Link zum Volltext

Verfügbarkeit prüfen

In Response to "Comment on Ensuring the Efficacy and Safety of Approved Medications"

Journal of medical toxicology, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

ACMT Comment on Recent Guidance on PFAS Laboratory Testing

Journal of medical toxicology, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Correction: American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time

Journal of medical toxicology, 2024, Vol.20 (1), p.75-75

2024

Link zum Volltext

Verfügbarkeit prüfen

American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time

Journal of medical toxicology, 2024, Vol.20 (1), p.64-67

2024

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Medication Shortages During Coronavirus Disease Pandemic

Journal of medical toxicology, 2020-07, Vol.16 (3), p.346-348

2020

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic

Journal of medical toxicology, 2020-07, Vol.16 (3), p.342-345

2020

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Limiting Harms of Vaping and E-cigarette Use

Journal of medical toxicology, 2021-01, Vol.17 (1), p.87-90

2021

Link zum Volltext

Verfügbarkeit prüfen

ACMT and AACT position statement: preventing occupational fentanyl and fentanyl analog exposure to emergency responders

Clinical toxicology (Philadelphia, Pa.), 2018-04, Vol.56 (4), p.297-300

2018

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Interpretation of Urine for Tetrahydrocannabinol Metabolites

Journal of medical toxicology, 2020-04, Vol.16 (2), p.240-242

2020

Link zum Volltext

Verfügbarkeit prüfen

Choosing Opioid Policies Our Patients Can Live With

Academic emergency medicine, 2016-11, Vol.23 (11), p.1290-1292

2016

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Buprenorphine Administration in the Emergency Department

Journal of medical toxicology, 2019-07, Vol.15 (3), p.215-216

2019

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: End the Use of the Term “Excited Delirium”

Journal of medical toxicology, 2023-07, Vol.19 (3), p.310-312

2023

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder

Journal of medical toxicology, 2019-10, Vol.15 (4), p.307-309

2019

Link zum Volltext

Verfügbarkeit prüfen

Self-reported cocaine use is not associated with elevations in high-sensitivity troponin I

Clinical toxicology (Philadelphia, Pa.), 2017-06, Vol.55 (5), p.332-337

2017

Link zum Volltext

Verfügbarkeit prüfen

ACMT Position Statement: Medication Administration and Safety During the Response to COVID-19 Pandemic

Journal of medical toxicology, 2020-10, Vol.16 (4), p.481-483

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(69)
Buchkapitel
(1)

Sprache

Englisch
(70)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Reporting of sexually transmitted infections during the COVID-19 pandemic

ACMT Position Statement: Position on the Recent Judicial Challenge of U.S. Food and Drug Administration Approval of Mifepristone

Reporting of Infectious Diseases in the United States During the Coronavirus Disease 2019 (COVID-19) Pandemic

ACMT Position Statement: Role of the Medical Toxicologist in the Management of Patients with Substance Use Disorder

Case Series: Pneumorrhachis Secondary to Spontaneous Pneumomediastinum

Bradycardia and Hypotension after Synthetic Cannabinoid Use: A Case Series

Severe prolonged agitation due to intranasal naloxone overexposure

American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time

The Landscape of Prescription Drug Shortages During the COVID-19 Pandemic

Ensuring the Efficacy and Safety of Approved Medications

In Response to "Comment on Ensuring the Efficacy and Safety of Approved Medications"

ACMT Comment on Recent Guidance on PFAS Laboratory Testing

Correction: American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time

American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time

ACMT Position Statement: Medication Shortages During Coronavirus Disease Pandemic

ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic

ACMT Position Statement: Limiting Harms of Vaping and E-cigarette Use

ACMT and AACT position statement: preventing occupational fentanyl and fentanyl analog exposure to emergency responders

ACMT Position Statement: Interpretation of Urine for Tetrahydrocannabinol Metabolites

Choosing Opioid Policies Our Patients Can Live With

ACMT Position Statement: Buprenorphine Administration in the Emergency Department

ACMT Position Statement: End the Use of the Term “Excited Delirium”

ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder

Self-reported cocaine use is not associated with elevations in high-sensitivity troponin I

ACMT Position Statement: Medication Administration and Safety During the Response to COVID-19 Pandemic

Suchergebnisse filtern